Aardvark Therapeutics’ (AARD) “Overweight” Rating Reiterated at Cantor Fitzgerald

Aardvark Therapeutics (NASDAQ:AARD)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $50.00 price objective on the stock.

Other research analysts have also issued reports about the stock. Bank of America lifted their price objective on shares of Aardvark Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Thursday, March 27th. Royal Bank of Canada initiated coverage on shares of Aardvark Therapeutics in a research note on Monday, March 10th. They issued an “outperform” rating and a $21.00 price target for the company. Finally, Morgan Stanley assumed coverage on Aardvark Therapeutics in a report on Monday, March 10th. They set an “overweight” rating and a $29.00 price objective on the stock.

Aardvark Therapeutics Trading Up 4.8 %

Aardvark Therapeutics stock traded up $0.36 during trading on Tuesday, hitting $7.87. The stock had a trading volume of 16,835 shares, compared to its average volume of 139,039. Aardvark Therapeutics has a 1 year low of $6.79 and a 1 year high of $19.58.

Insiders Place Their Bets

In other Aardvark Therapeutics news, CEO Tien-Li Lee bought 16,542 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $264,672.00. Following the acquisition, the chief executive officer now owns 1,496,175 shares in the company, valued at approximately $23,938,800. This represents a 1.12 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Nelson Sun bought 10,000 shares of Aardvark Therapeutics stock in a transaction dated Friday, February 14th. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $160,000.00. Following the completion of the transaction, the chief financial officer now directly owns 99,484 shares in the company, valued at approximately $1,591,744. This trade represents a 11.18 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.